MapLight Therapeutics, Inc. Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the th ...

It was the Angels who helped make sure the Astros didn’t reach the playoffs for the first time in eight seasons last ...

AI-generated abuse content surged in 2025, with watchdogs warning that the technology is making harmful material easier to create and spread.

OpenAI announced it would shut down Sora. Here's why, and what it means for you and the future of AI in the workforce.

Find autism and neurodiversity support close to home at Nogales’ free Neurodiversity Community Resource Fair on April 2.